[The course of coronary heart disease concurrent with peptic ulcer disease: clinical and pathogenetic aspects]
Related Experiment Video
Updated: Apr 30, 2026
Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
Published on: November 1, 2024
Insights
Eradication therapy significantly improved coronary heart disease (CHD) symptoms, reducing angina and nitroglycerin use. This therapy positively impacts CHD patients with concurrent peptic ulcer disease (PUD).
Area of Science:
- Cardiology
- Gastroenterology
Context:
- Coronary heart disease (CHD) and peptic ulcer disease (PUD) often coexist.
- Evaluating integrated treatment strategies is crucial for managing patients with multiple comorbidities.
Purpose:
- To assess the efficacy of eradication therapy in patients suffering from both CHD and PUD.
- To compare eradication therapy against antisecretory therapy and standard CHD treatment.
Summary:
- A study involving 112 patients with concurrent CHD and PUD randomized them into three groups: eradication therapy, antisecretory therapy, or CHD treatment alone.
- Eradication therapy led to a 62.6% reduction in angina attacks, a 70.4% decrease in nitroglycerin use, and a 45.3% increase in exercise tolerance.
- Antisecretory therapy showed moderate improvements, while the control group had no significant changes.
Impact:
- Eradication therapy demonstrates a significant antianginal effect, improving the clinical course of CHD in patients with PUD.
- This suggests a link between H. pylori eradication and cardiovascular health improvements.
- Findings support incorporating eradication therapy into the management of patients with comorbid CHD and PUD.
Aim:
To make a comprehensive evaluation of the efficiency of eradication therapy in patients with coronary heart disease (CHD) concurrent with peptic ulcer disease (PUD).
Subjects And Methods:
The results of treatment were studied in 112 patients with CHD concurrent with PUD who were randomized into 3 groups: 1) adequate eradication therapy during treatment for CHD; 2) antisecretory therapy; 3) treatment for CHD only. The trend in the clinical symptoms of the diseases and the results of an exercise test were assessed.
Results:
After eradication therapy, Group 1 patients displayed a reduction in the frequency of angina attacks by 62.6% and weekly nitroglycerin needs by 70.4% and an increase in exercise tolerance by 45.3%. In Group 2 patients on antisecretory therapy, the similar indicators changed by 30.7, 21.2, and 26.5%, respectively. Group 3 patients showed no significant change in the study indicators.
Conclusion:
The findings suggest that eradication therapy has a positive impact on the course of CHD, which manifests itself as an antianginal effect and hence a change in the clinical picture.
Related Concept Videos
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:24Peptic Ulcer Disease II: Pathophysiology
01:25Peptic Ulcer Disease III: Clinical Manifestations and Complications
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:25Peptic Ulcer Disease I: Introduction
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...